This site is intended for healthcare professionals

CPD
CPD
Pro
Pro
Sign in
Go to /sign-in page

You can view 5 more pages before signing in

Go to /pro/cpd-dashboard page

This page is worth 0.05 CPD credits. CPD dashboard

Go to /account/subscription-details page

This page is worth 0.05 CPD credits. Upgrade to Pro

Pulmonary hypertension in sarcoidosis

Last reviewed dd mmm yyyy. Last edited dd mmm yyyy

Authoring team

Pulmonary hypertension is a well described complication associated with an increased risk of mortality (1).

  • the incidence in a large Japanese study has been estimated to be around 5% (1)
  • it is elevated in 6 to 23% of patients at rest and in 43% with exertion (2)

The mechanism for pulmonary hypertension can be due to

  • fibrosis - the most common mechanism which results in obliteration of the pulmonary vessels
  • external compression from the enlarged lymphnodes
  • granulomatous infiltration of the pulmonary arterioles

Sildenafil has been reported to significantly improve the haemodynamic parameters but the effectiveness of other pulmonary vasodilator therapy is currently unknown (1)

Reference:

Related pages

Create an account to add page annotations

Create a free account

Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.

The content herein is provided for informational purposes and does not replace the need to apply professional clinical judgement when diagnosing or treating any medical condition. A licensed medical practitioner should be consulted for diagnosis and treatment of any and all medical conditions.

Connect

Copyright 2024 Oxbridge Solutions Limited, a subsidiary of OmniaMed Communications Limited. All rights reserved. Any distribution or duplication of the information contained herein is strictly prohibited. Oxbridge Solutions receives funding from advertising but maintains editorial independence.